(Q34532732)

2 August 2017

Olsalazine versus placebo in the treatment of mild to moderate ulcerative colitis: a randomised double blind trial (English)

1 reference

2 August 2017

0 references

1 reference

Feurle GE

1

1 reference

2 August 2017

Theuer D

2

1 reference

2 August 2017

Velasco S

3

1 reference

2 August 2017

Barry BA

4

1 reference

2 August 2017

Wördehoff D

5

1 reference

2 August 2017

Sommer A

6

1 reference

2 August 2017

Jantschek G

7

1 reference

2 August 2017

Kruis W

8

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 October 1989

1 reference

2 August 2017

1 reference

2 August 2017

30

1 reference

2 August 2017

1354-1361

1 reference

2 August 2017

10

1 reference

CONTROLLED TRIAL OF SULPHASALAZINE IN THE TREATMENT OF ULCERATIVE COLITIS.

2 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1434384

An oral preparation to release drugs in the human colon

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1434384

Predictors of duodenal ulcer healing and relapse

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1434384

Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1434384

Acetylator phenotype and adverse effects of sulphasalazine in healthy subjects

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1434384

Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1434384

Salicylates for the sulfa-sensitive patient with ulcerative colitis?

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1434384

Olsalazine in active ulcerative colitis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1434384

Induction of and adaptation to olsalazine induced intestinal volume load.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1434384

Double-blind comparison of olsalazine and sulphasalazine in active ulcerative colitis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1434384

Sulphasalazine: a review of 40 years' experience.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1434384

Modulation of human colonic arachidonic acid metabolism by sulfasalazine.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1434384

Disposition of disodium azodisalicylate in healthy subjects. A possible new drug for inflammatory bowel disease

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1434384

An experiment to determine the active therapeutic moiety of sulphasalazine

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1434384

Hemolysis during salicylazosulfapyridine therapy

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1434384

Clinical Pharmacokinetics of Sulphasalazine

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1434384

Biopsy studies in ulcerative colitis.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1434384

Distribution and metabolism in healthy volunteers of disodium azodisalicylate, a potential therapeutic agent for ulcerative colitis

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1434384

Distribution studies of salicylazosulfapyridine and its metabolites

27 October 2018

1 reference

12 December 2020

Therapeutic Efficacy of Sulfasalazine and Its Metabolites in Patients with Ulcerative Colitis and Crohn's Disease

1 reference

12 December 2020

Salicylazobenzoic acid in ulcerative colitis

1 reference

12 December 2020

5-aminosalicylic acid in a slow-release preparation: bioavailability, plasma level, and excretion in humans

1 reference

12 December 2020

A polymeric drug for treatment of inflammatory bowel disease

1 reference

12 December 2020

Colonic azodisalicylate metabolism determined by in vivo dialysis in healthy volunteers and patients with ulcerative colitis

1 reference

12 December 2020

Absorption and excretion of a single 1-g dose of azodisal sodium in subjects with ileostomy

1 reference

12 December 2020

A new slow-release form of 5-aminosalicylic acid for the oral treatment of inflammatory bowel disease. Biopharmaceutic and clinical pharmacokinetic characteristics

1 reference

12 December 2020

Azodisal sodium in the treatment of ulcerative colitis. A study of tolerance and relapse-prevention properties

1 reference

12 December 2020

Enhanced formation of sulfidopeptide-leukotrienes in ulcerative colitis and Crohn's disease: inhibition by sulfasalazine and 5-aminosalicylic acid

1 reference

12 December 2020

Clinical experience of the tolerance of mesalazine and olsalazine in patients intolerant of sulphasalazine

1 reference

12 December 2020

Olsalazine sodium in the treatment of ulcerative colitis among patients intolerant of sulfasalazine. A prospective, randomized, placebo-controlled, double-blind, dose-ranging clinical trial

1 reference

12 December 2020

Controlled trial comparing olsalazine and sulphasalazine for maintenance treatment of ulcerative colitis

1 reference

12 December 2020

Treatment of ulcerative colitis with olsalazine and sulphasalazine: efficacy and side-effects

1 reference

12 December 2020

Sulphasalazine and salicylazosulphadimidine in ulcerative colitis

1 reference

12 December 2020

Identifiers

DOI

10.1136/GUT.30.10.1354

1 reference

2 August 2017

1 reference

2 August 2017

1 reference